Veregen is owned by Ani Pharms.
Veregen contains Sinecatechins.
Veregen has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Veregen are:
Veregen was authorised for market use on 31 October, 2006.
Veregen is available in ointment;topical dosage forms.
Veregen can be used as treatment of genital warts.
The generics of Veregen are possible to be released after 02 October, 2026.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10434059 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Nov, 2022
(2 months ago) | |
US9770406 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Jul, 2025
(2 years from now) | |
US7858662 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Oct, 2026
(3 years from now) |
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Treatment: Treatment of genital warts
Dosage: OINTMENT;TOPICAL
5
United States
4
European Union
3
Germany
2
Hong Kong
2
Spain
1
Austria
1
Korea, Republic of
1
Brazil
1
Australia
1
Israel
1
Cyprus
1
Mexico
1
Japan
1
Argentina
1
South Africa
1
Portugal
1
Belgium
1
Russia
1
China
1
Canada
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic